A prospective, randomized, open-label, twenty-six week study of the efficacy and safety of converting kidney and liver transplant recipients with tacrolimus-associated abnormal glucose metabolism to cyclosporine micro-emulsion with C2 monitoring
Phase of Trial: Phase IV
Latest Information Update: 17 Feb 2011
At a glance
- Drugs Ciclosporin; Tacrolimus
- Indications Liver transplant rejection; Renal transplant rejection
- Focus Pharmacodynamics
- Sponsors Novartis
- 17 Feb 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Dec 2005 New trial record.